Company Profile

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE290.9012.6 (+4.53 % )
PREV CLOSE (Rs.) 278.30
OPEN PRICE (Rs.) 278.50
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 193124
TODAY'S LOW / HIGH (Rs.)278.30 295.80
52 WK LOW / HIGH (Rs.)211.3 323.3
NSE290.95 12.55 (+4.51 % )
PREV CLOSE(Rs.) 278.40
OPEN PRICE (Rs.) 278.10
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 290.95 (2332 )
VOLUME 6293405
TODAY'S LOW / HIGH(Rs.) 277.90 295.85
52 WK LOW / HIGH (Rs.)211.05 323.5

Company News

Date Heading Details
01-Apr-2020 Biocon's arm receives EIR from USFDA for Malaysia facility <p align="justify">Biocon subsidiary -- Biocon Sdn Bhd has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) of its Insulins manufacturing facility in Malaysia, for Insulin Glargine. The inspection was conducted between February 10 and February 21, 2020.</p><p align="justify">The Inspection has been closed with a ‘VAI' (Voluntary Action Indicated) classification in the EIR, for the three observations issued at the conclusion of the inspection in Feb 2020. </p><p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.<br></p>
01-Apr-2020 Biocon gains on receiving EIR from USFDA for Malaysia facility <div align="justify">Biocon is currently trading at Rs. 276.35, up by 5.75 points or 2.12% from its previous closing of Rs. 270.60 on the BSE.<br><br></div><div align="justify">The scrip opened at Rs. 280.00 and has touched a high and low of Rs. 285.40 and Rs. 274.55 respectively. So far 91051 shares were traded on the counter.<br><br></div><div align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 323.30 on 24-Feb-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.<br><br></div><div align="justify">Last one week high and low of the scrip stood at Rs. 290.50 and Rs. 268.20 respectively. The current market cap of the company is Rs. 33150.00 crore.<br><br></div><div align="justify">The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 21.64% and 17.70% respectively.<br><br></div><div align="justify">Biocon subsidiary -- Biocon Sdn Bhd has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) of its Insulins manufacturing facility in Malaysia, for Insulin Glargine. The inspection was conducted between February 10 and February 21, 2020.<br><br></div><div align="justify">The Inspection has been closed with a ‘VAI' (Voluntary Action Indicated) classification in the EIR, for the three observations issued at the conclusion of the inspection in Feb 2020. <br><br></div><div align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.</div><div align="justify"><br></div>
27-Mar-2020 Biocon, its arm ensuring manufacturing of life-saving medicines for patients <p align="justify">Biocon and its subsidiary -- Biocon Biologics -- have activated business continuity plans across their functions to prepare for unforeseen events in light of the evolving COVID19 situation and to meet the needs of patients, partners, customers and other stakeholders who depend on their products.</p><p align="justify">The government of India has announced a 21-day nationwide lockdown on March 24, 2020, but permitted ‘essential services' such as manufacturing of pharmaceuticals to continue. The company will continue to operate essential pharmaceutical manufacturing in full compliance with government requirements.</p><p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.<br></p>
20-Mar-2020 Biocon receives EIR from USFDA for manufacturing facility in Bengaluru <p align="justify">Biocon has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for the Post-Approval and GMP inspection of its Small Molecules API Manufacturing Facility at 20th KM, Biocon Campus, Bengaluru, conducted between February 20, 2020 and February 26, 2020. <p align="justify">The EIR has been closed with a VAI classification for the observations. At the conclusion of the inspection in February, the agency had issued a Form 483, with two observations, which were procedural in nature and are being addressed by the company. <p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.</p>
20-Mar-2020 Biocon informs about company updates <p align="justify">Biocon has informed that the company has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the Post-Approval and GMP inspection of its Small Molecules API Manufacturing Facility at 20th KM, Biocon Campus, Bengaluru, conducted between Feb 20 and Feb 26, 2020. The EIR has been closed with a VAI classification for the observations. At the conclusion of the inspection last month the agency had issued a Form 483, with two observations, which were procedural in nature and are being addressed by the Company. </p><p>The above information is a part of company's filings submitted to BSE.<br></p>
20-Mar-2020 Biocon jumps on receiving EIR from USFDA for manufacturing facility in Bengaluru <p align="justify">Biocon is currently trading at Rs. 261.00, up by 8.45 points or 3.35% from its previous closing of Rs. 252.55 on the BSE.<p align="justify">The scrip opened at Rs. 259.80 and has touched a high and low of Rs. 262.55 and Rs. 253.70 respectively. So far 49711 shares were traded on the counter.<p align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 323.30 on 24-Feb-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.<p align="justify">Last one week high and low of the scrip stood at Rs. 287.35 and Rs. 235.80 respectively. The current market cap of the company is Rs. 31266.00 crore.<p align="justify">The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 21.64% and 17.70% respectively.<p align="justify">Biocon has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for the Post-Approval and GMP inspection of its Small Molecules API Manufacturing Facility at 20th KM, Biocon Campus, Bengaluru, conducted between February 20, 2020 and February 26, 2020. <p align="justify">The EIR has been closed with a VAI classification for the observations. At the conclusion of the inspection in February, the agency had issued a Form 483, with two observations, which were procedural in nature and are being addressed by the company. <p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.</p>
12-Mar-2020 Biocon, Mylan win patent litigation asserted by Sanofi for insulin Glargine device patent in US <p align="justify">Biocon has won a US court ruling that invalidated a Sanofi patent on the Insulin Glargine device, removing a key legal hurdle to commercializing Semglee (Insulin Glargine) co-developed with Mylan, in the US.</p><p align="justify">The US District Court of New Jersey found the device patent claims (US Patent No. 9,526,844) asserted by Sanofi against Biocon and Mylan's Insulin Glargine product 'not infringed' and 'invalid' for lack of written description. Separately, as previously announced, Sanofi's formulation patents (US Patent No. 7,476,652 and US Patent No. 7,713,930) were previously affirmed to be invalid by the Federal Circuit.</p><p align="justify">The 505(b) (2) New Drug Application (NDA) for Semglee is under active review by the US Food and Drug Administration (USFDA). The USFDA has set a Target Action Date for company's Insulin Glargine application in June 2020. Biocon remains confident of being able to commercialize the product in calendar year 2020. The market opportunity for Insulin Glargine in the US is estimated at $2.2 billion.<br></p><p align="justify"><p align="justify">Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.</p>
12-Mar-2020 M&M, Biocon and NHPC to see some action today <p align="justify"><strong>Mahindra &amp; Mahindra</strong> (M&amp;M) has signed a Share Purchase Agreement for purchase of additional 34,249 Equity Shares of M.I.T.R.A. Agro Equipments (Mitra), an Associate of the Company, from its existing shareholders. The company currently holds 26% (on a fully diluted basis) of the equity share capital of Mitra, and post completion of the above transaction, the company will hold approximately 39% of the equity share capital of Mitra on a fully diluted basis.<p align="justify"><strong>Biocon</strong> has won a U.S. court ruling that invalidated a Sanofi patent on the Insulin Glargine device, removing a key legal hurdle to commercializing Semglee (Insulin Glargine) co-developed with Mylan, in the U.S.<p align="justify"><strong>NHPC</strong> has raised Rs 500 crore on through private placement of secured, redeemable, taxable, non-cumulative, non-convertible 6.89% NHPC AA-1 Series Bonds.<p align="justify"><strong>SMS Pharmaceuticals</strong> has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its API facility situated at Kandivalasa, Andhra Pradesh. The USFDA had inspected the said facility during the period January 13, 2020 to January 17, 2020. This facility predominantly caters regulated markets including USA.<p align="justify"><strong>KPIT Technologies</strong> has entered into an agreement with Vayavya Labs (VL) and its shareholders for acquiring majority stake in VL. The proposed acquisition of VL will give the company a head start in the field of simulation and embedded software automation, across the focus practices of KPIT. It will also help in creating a differentiated positioning and a definite early mover advantage in newer opportunities in the areas of simulation.<p align="justify"><strong>Canara Bank</strong> has raised Rs 3000 crore through the allotment of Unsecured Rated Listed Subordinated Non Convertible Fully Paid up Taxable Redeemable Basel III Compliant Tier II Bonds - Series I 2019-20 with a coupon rate of 7.18 per cent.<p align="justify"><strong>Bajaj Auto</strong> has launched Dominar 250, a variant of the Dominar Sports Tourer model, priced at Rs 1.6 lakh (ex-showroom in Delhi). The Dominar 250 is powered by a liquid cooled 248.8 cc engine delivering 27 PS power. BS-VI compliant new Dominar 250 is now available across all Bajaj Auto dealerships in dual channel ABS variant. </p>
11-Mar-2020 Announcement under Regulation 30 (LODR)-Press Release / Media Release Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin Glargine Device Patent in U.S.
09-Mar-2020 Announcement under Regulation 30 (LODR)-Press Release / Media Release U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon''s Proposed Biosimilar Bevacizumab for Review